Targeting and stabilizing distinct kinase conformations is an instrumental strategy for dissecting conformation-dependent signaling of protein kinases. Herein the structure-based design, synthesis, and evaluation of pleckstrin homology (PH) domain-dependent covalent-allosteric inhibitors (CAIs) of the kinase Akt is reported. These inhibitors bind covalently to a distinct cysteine of the kinase and thereby stabilize the inactive kinase conformation. These modulators exhibit high potency and selectivity, and represent an innovative approach for chemical biology and medicinal chemistry research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/anie.201502142 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
AKT kinases as therapeutic targets.
J Exp Clin Cancer Res
November 2024
Nuclear Dynamics and Cancer Program, Cancer Epigenetics Institute, Institute for Cancer Research, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
Article Synopsis
- AKT, a key protein kinase in the PI3K signaling pathway, is crucial for normal cell functions and can contribute to diseases like cancer, inflammation, and autoimmune disorders when its regulation fails.
- Targeting the PI3K/AKT pathway is essential to counteract these diseases, with current AKT inhibitors showing promise but facing challenges like resistance and side effects.
- The review highlights innovative targeting strategies, such as isoform-specific approaches and selective inhibitors, alongside the search for reliable biomarkers to improve treatment efficacy and patient outcomes.
Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises.
J Med Chem
April 2024
Department of Chemistry and Chemical Biology, TU Dortmund University and Drug Discovery Hub Dortmund (DDHD), Zentrum für Integrierte Wirkstoffforschung (ZIW), Otto-Hahn-Strasse 4a, 44227 Dortmund, Germany.
Article Synopsis
- - Akt kinase plays a crucial role in cell functions such as growth, survival, metabolism, and migration, and its dysregulation is linked to cancer and metabolic disorders.
- - Research into Akt inhibitors aims to counteract overactive Akt signaling, with three main types: ATP-competitive, allosteric, and covalent-allosteric inhibitors, each functioning in different ways to inhibit Akt activity.
- - Capivasertib, an ATP-competitive inhibitor, was recently approved by the FDA for breast cancer treatment, but challenges like selectivity, biomarker identification, and reducing side effects remain, especially for covalent-allosteric inhibitors that show promise for future therapies.
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020-2023).
Expert Opin Ther Pat
April 2024
DSC 309, Department of Chemistry, The University of Nebraska at Omaha, Omaha, NE, USA.
Introduction: Recent years have seen significant strides in drug developmenttargeting the EGFR/RAS/RAF signaling pathway which is critical forcell growth and proliferation. Protein-protein interaction networksamong EGFR, RAS, and RAF proteins offer insights for drug discovery. This review discusses the drug design and development efforts ofinhibitors targeting these proteins over the past 3 years, detailingtheir structures, selectivity, efficacy, and combination therapy.
View Article and Find Full Text PDFBiophysical and Biochemical Characterization of Structurally Diverse Small Molecule Hits for KRAS Inhibition.
Chembiochem
April 2024
Department of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, 6431 Fannin St., Houston, Texas, 77030, USA.
We describe six compounds as early hits for the development of direct inhibitors of KRAS, an important anticancer drug target. We show that these compounds bind to KRAS with affinities in the low micromolar range and exert different effects on its interactions with binding partners. Some of the compounds exhibit selective binding to the activated form of KRAS and inhibit signal transduction through both the MAPK or the phosphatidylinositide 3-kinase PI3K-protein kinase B (AKT) pathway in cells expressing mutant KRAS.
View Article and Find Full Text PDFSystematic Analysis of Covalent and Allosteric Protein Kinase Inhibitors.
Molecules
August 2023
LIMES Program Unit Chemical Biology and Medicinal Chemistry, Department of Life Science Informatics, B-IT, Rheinische Friedrich-Wilhelms-Universität, Friedrich-Hirzebruch-Allee 5/6, D-53115 Bonn, Germany.
In drug discovery, protein kinase inhibitors (PKIs) are intensely investigated as drug candidates in different therapeutic areas. While ATP site-directed, non-covalent PKIs have long been a focal point in protein kinase (PK) drug discovery, in recent years, there has been increasing interest in allosteric PKIs (APKIs), which are expected to have high kinase selectivity. In addition, as compounds acting by covalent mechanisms experience a renaissance in drug discovery, there is also increasing interest in covalent PKIs (CPKIs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!